Novartis (NYSE:NVS)‘s stock had its “neutral” rating reaffirmed by stock analysts at Deutsche Bank in a report released on Friday.
A number of other research analysts also recently issued reports on the company. JPMorgan Chase restated a “neutral” rating on shares of Novartis in a report on Monday, April 9th. UBS restated a “neutral” rating on shares of Novartis in a report on Monday, January 15th. Zacks Investment Research downgraded Novartis from a “hold” rating to a “sell” rating in a report on Tuesday, January 2nd. Finally, Nord/LB restated a “neutral” rating on shares of Novartis in a report on Tuesday, January 2nd. Four equities research analysts have rated the stock with a sell rating, eight have given a hold rating and one has assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $87.51.
Shares of NYSE:NVS opened at $77.88 on Friday. Novartis has a 1 year low of $73.31 and a 1 year high of $94.19. The stock has a market cap of $183,079.03, a P/E ratio of 16.19, a price-to-earnings-growth ratio of 1.79 and a beta of 0.74. The company has a current ratio of 1.21, a quick ratio of 0.91 and a debt-to-equity ratio of 0.31.
Novartis (NYSE:NVS) last announced its quarterly earnings results on Thursday, April 19th. The company reported $1.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.25 by $0.03. Novartis had a return on equity of 16.18% and a net margin of 16.04%. The company had revenue of $12.69 billion for the quarter, compared to the consensus estimate of $12.45 billion. During the same quarter in the previous year, the business earned $1.13 EPS. Novartis’s revenue was up 10.0% compared to the same quarter last year. analysts expect that Novartis will post 5.28 earnings per share for the current fiscal year.
Several hedge funds have recently bought and sold shares of the business. Garland Capital Management Inc. grew its holdings in shares of Novartis by 1.0% during the 4th quarter. Garland Capital Management Inc. now owns 52,233 shares of the company’s stock worth $4,385,000 after acquiring an additional 535 shares during the period. Tradition Capital Management LLC grew its holdings in shares of Novartis by 0.9% during the 4th quarter. Tradition Capital Management LLC now owns 69,381 shares of the company’s stock worth $5,825,000 after acquiring an additional 652 shares during the period. Commerce Bank grew its holdings in shares of Novartis by 2.4% during the 4th quarter. Commerce Bank now owns 28,004 shares of the company’s stock worth $2,352,000 after acquiring an additional 664 shares during the period. West Oak Capital LLC grew its holdings in shares of Novartis by 4.4% during the 4th quarter. West Oak Capital LLC now owns 15,860 shares of the company’s stock worth $1,332,000 after acquiring an additional 665 shares during the period. Finally, Cambridge Investment Research Advisors Inc. grew its holdings in shares of Novartis by 1.6% during the 4th quarter. Cambridge Investment Research Advisors Inc. now owns 45,425 shares of the company’s stock worth $3,814,000 after acquiring an additional 716 shares during the period. Hedge funds and other institutional investors own 10.76% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This piece of content was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of international copyright legislation. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/04/22/novartis-nvs-earns-neutral-rating-from-deutsche-bank.html.
Novartis Company Profile
Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for patients and health-care providers. This segment also commercializes products in the areas of oncology and rare diseases, ophthalmology, immunology and dermatology, neuroscience, respiratory, cardio-metabolic, and established medicines.
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.